Altamira Therapeutics (FRA:2QA) Research & Development: €2.96 Mil (TTM As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics Research & Development?

Altamira Therapeutics FRA:2QA 30 Research & Development is €2.96 Mil as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Altamira Therapeutics's Research & Development for the six months ended in Jun. 2025 was €1.27 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was €2.96 Mil.

Altamira Therapeutics  (FRA:2QA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Altamira Therapeutics Research & Development Related Terms

Altamira Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Research & Development Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.69 3.10 14.45 3.10 3.56

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.74 1.83 1.68 1.27
FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €2.96 Mil mean?
Altamira Therapeutics (FRA:2QA) has a Research & Development of €2.96 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Research & Development too high?
Altamira Therapeutics' current Research & Development is €2.96 Mil. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' Research & Development compare to IOBTQ and SCPX?
Altamira Therapeutics' Research & Development of €2.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Altamira Therapeutics and its competitors. Altamira Therapeutics's current Research & Development is €2.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current Research & Development of €2.96 Mil. The current Research & Development is €2.96 Mil. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current Research & Development is €2.96 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price